By Measuring The Effect On A Living Organism, Tissue, Or Cell Patents (Class 506/10)
  • Patent number: 12006515
    Abstract: Provided is a method for preparing mesenchymal stem cell-conditioned medium, including isolating mesenchymal stem cells from a subject, maintaining the mesenchymal stem cells in a mesenchymal stem cell maintenance medium, collecting the mesenchymal stem cells at passages 2 to 5, culturing the mesenchymal stem cells in a medium supplemented with fetal bovine serum and mesenchymal stem cell culture adjuvant for hours to obtain a mesenchymal stem cell-conditioned medium, harvesting the medium and centrifuging followed by filtering. Also provided is a method for preventing or treating epithelial tissue disorder of eyes such as dry eye syndrome, including applying the medium to an eye of a subject. Further provided is a medical composition including the medium.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: June 11, 2024
    Assignee: Buddhist Tzu Chi Medical Foundation
    Inventors: Yuan-Chieh Lee, Li-Yi Sun
  • Patent number: 11994456
    Abstract: The present disclosure provides, among other things, methods and devices for single cells/particle selection and isolation from a sample in a light-curable biomatrix gel. The individual cells or particles are observed by microscopy and manipulated and isolated by accurately controlling the light transmission from a liquid crystal display (LCD) oriented under the sample to provide a detailed image of the sample. In some embodiments, selected cells or particles are then immobilized by curing the biomatrix gel with blue/violet light transmitted from a LED pixel array. In other embodiments, the selected cells or particles of interest are allowed to remain mobile. In either embodiment, the individual cells or particles of interest are segregated from and isolated from the remainder of the sample.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: May 28, 2024
    Assignee: ENRICH BIOSYSTEMS INC.
    Inventor: Qi Zhao
  • Patent number: 11953421
    Abstract: The analysis method includes a step of measuring cytometry parameters for each biological cell contained in a biological sample; a step of determining, for each biological cell of the biological sample, a point in a N-dimensional space whose coordinates are defined depending on the cytometry parameters measured for the corresponding biological cell, where N is an integer greater than or equal to 3; a step of automatic clustering of the points into different cell clusters depending on the measured cytometry parameters, so as to define a sample cluster file; and a step of comparing the sample cluster files with reference cluster files, each of the reference cluster files being defined from cytometry parameters of a respective pathological or abnormal biological sample.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: April 9, 2024
    Assignee: DIAGNOSTICA STAGO
    Inventor: Alain Rousseau
  • Patent number: 11939579
    Abstract: The present invention relates to a tissue-specific promoter system for expressing microRNA (miRNA) for RNA interference-based methods of gene therapy. In these systems, the miRNA will inhibit gene expression or replace natural miRNA expression using microRNA.
    Type: Grant
    Filed: April 26, 2022
    Date of Patent: March 26, 2024
    Assignee: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
    Inventor: Scott Quenton Harper
  • Patent number: 11932862
    Abstract: Polynucleotides comprising genetic regulatory elements, as well as constructs, host cells, and transgenic organisms comprising the same are described. The polynucleotides can control the expression of an operably linked gene in a host cell or organism, such as a plant cell or a plant. Methods of using the polynucleotide to control the expression of an operably linked gene of interest in a plant or plant cell are further provided.
    Type: Grant
    Filed: February 2, 2021
    Date of Patent: March 19, 2024
    Assignee: Monsanto Technology LLC
    Inventors: Ian W. Davis, Tedd D. Elich
  • Patent number: 11913017
    Abstract: A guide RNA comprising: a gRNA spacer sequence at the 5? end of the guide RNA, wherein the spacer sequence is complementary to a target gene, a scaffold sequence that binds to Cas9, and an RNA capture and sequencing domain comprising: a barcode sequence, and a primer binding sequence; nucleic acids and vectors encoding the guide RNA; cells expressing the guide RNA; and a library comprising a plurality of guide RNAs. Also disclosed are methods of introducing a genetic perturbation into a cell, methods of assessing an effect of at least one genetic perturbation on RNA expression in a cell, methods of identifying nucleic acid sequences associated with a disease state and a method of identifying candidate therapeutic agents.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: February 27, 2024
    Assignee: The Regents of the University of California
    Inventors: Kun Zhang, Prashant Mali, Yan Wu, Dongxin Zhao
  • Patent number: 11905324
    Abstract: The authors of the present invention designed a new fluorescent fusion polypeptide comprising a membrane localization peptide, a peptide capable of binding G-protein or tyrosine receptors following phosphorylation of these receptors by GRKs or RTKs, a vesicularization peptide and a fluorescent peptide. This biosensor is formed by two peptides targeted to two different cellular compartments, allowing the detection of the translocation of GRKs (G-protein receptor kinases) and/or beta-arrestin or Receptor tyrosine kinases (RTKs) from the cell cytoplasm to the cell cytoplasmic membrane in vivo by monitoring the distribution of the fluorescent polypeptide within the cellular cytoplasm.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: February 20, 2024
    Assignee: INNOVATIVE TECHNOLOGIES IN BIOLOGICAL SYSTEMS SL
    Inventors: Patricia Villace Lozano, Rosa Maria Mella Lopez, Danel Kortazar Zaballa, Jorge Gamiz Mata, Aida Clarisa Salado Pogonza
  • Patent number: 11883440
    Abstract: Provided are vesicles derived from bacteria belonging to the genus Proteus and a use thereof. The inventors of the present invention experimentally confirmed that the vesicles was significantly reduced in samples of patients with cancers, allergic-respiratory diseases, cardiovascular diseases, metabolic diseases, or neuropsychiatric diseases, as compared to that of normal people, and the vesicles inhibited the secretion of inflammatory mediators due to pathogenic vesicles and also exhibited anticancer efficacy. Therefore, it is anticipated that the vesicles derived from bacteria belonging to the genus Proteus, according to the present invention, may be usefully used for the development of a method of diagnosing cancer, cardiovascular diseases, metabolic diseases, neuropsychiatric diseases, allergic-respiratory diseases, and inflammatory bowel diseases, and a composition for prevention, treatment, and/or alleviation.
    Type: Grant
    Filed: February 15, 2021
    Date of Patent: January 30, 2024
    Assignee: MD HEALTHCARE INC.
    Inventor: Yoon-Keun Kim
  • Patent number: 11869191
    Abstract: A system for determining the viability of an embryo comprises an imaging device, an excitation device configured to direct an excitation energy at an embryo, a controller communicatively connected to the imaging device and the excitation device, configured to drive the excitation device and collect images from the imaging device at an imaging frequency, a processor performing steps comprising acquiring a set of images from the imaging device, performing a Fourier Transformation to generate a set of phasor coordinates, computing a D-trajectory, computing a set of values of additional parameters, comparing the set of values to a set of stored values related to embryos of known viability, and calculating a viability index factor of the embryo from the set of values and the set of stored values. Methods of calculating embryo viability and determining one or more properties of a tissue are also described.
    Type: Grant
    Filed: July 11, 2022
    Date of Patent: January 9, 2024
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Ning Ma, Michelle Digman, Hongtao Chen
  • Patent number: 11809792
    Abstract: Disclosed herein are microfluidic systems with recirculation of fluid and computer-implemented methods of calculating conditions within the microfluidic systems. The microfluidic systems include a computing device and a microfluidic device having first and second reservoirs, at least one chamber, and a fluid path connecting the first reservoir, the chamber, and the second reservoir. The methods for calculating conditions include receiving a first reservoir fluid volume, a second reservoir fluid volume, a first concentration, and a second concentration. The methods further include receiving a time-dependent imposed pressure difference between the first reservoir and the second reservoir, then determining a hydraulic pressure difference and an effective pressure difference. The effective pressure difference is used to account for reactions occurring within the microfluidic device and to determine the value of the condition within the microfluidic device.
    Type: Grant
    Filed: September 9, 2022
    Date of Patent: November 7, 2023
    Assignee: University of Central Florida Research Foundation
    Inventors: James Hickman, Kazi Tasneem, Christopher Long
  • Patent number: 11802315
    Abstract: The present invention relates to a method for determining or predicting the response of a patient diagnosed with non-small-cell lung carcinoma to targeted pharmacotherapy. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with non-small-cell lung carcinoma to specific medicaments. More specifically, the present invention provides methods which measure kinase-activity by studying phosphorylation levels and profiles and inhibitions thereof by drugs in blood samples of said patients.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: October 31, 2023
    Assignees: PamGene B.V., Erasmus University Medical Center Rotterdam
    Inventors: Robby Ruijtenbeek, Dirgje Maria Adriana Van Den Heuvel, Richard De Wijn, Joan Gertrudis Jacobus Victor Aerts, Adrianus Henricus Josephus Mathijssen
  • Patent number: 11788095
    Abstract: The present invention relates to a synthetic promoter capable of controlling the expression of a target gene at various locations in the genome of an acid-resistant strain, and more particularly to a synthetic promoter including a core promoter derived from an acid-resistant strain and an upstream activating sequence (UAS) element serving as an enhancer. When the present invention is applied to a variety of genetic and metabolic engineering techniques for acid-resistant yeast, various metabolic networks can be configured as desired while controlling the expression level of the target gene, so a method of producing various metabolites using acid-resistant yeast is provided, and the cost of producing the metabolites can be greatly reduced depending on the properties of the acid-resistant yeast.
    Type: Grant
    Filed: November 10, 2021
    Date of Patent: October 17, 2023
    Assignee: SK Innovation Co., Ltd.
    Inventors: Jae Yeon Park, Ki Sung Lee, Tae Young Lee
  • Patent number: 11789011
    Abstract: Described are three-dimensional, engineered, biological breast tissues, adipose tissues, and tumor models, including breast cancer models.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: October 17, 2023
    Inventors: Shelby Marie King, Deborah Lynn Greene Nguyen, Vivian A. Gorgen, Benjamin R. Shepherd, Sharon C. Presnell, Rosalie Sears, Brittany Allen-Petersen, Ellen Langer
  • Patent number: 11754575
    Abstract: Methods and systems for determining a dose of an analyte in an unknown sample on an instrument, such as a nucleic acid analyzer, immunoassay analyzer, or clinical chemistry analyzer using a reagent from a selected assay lot are described. The methods and systems use core dose-response information based on measurements of response values to a set of calibrators on a plurality of other instruments and assay lot-specific response information to calibrate the instrument.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: September 12, 2023
    Assignee: BECKMAN COULTER, INC.
    Inventors: Mark Holland, Conan Dewitt
  • Patent number: 11739383
    Abstract: A honeycomb tube with a planar frame defining a fluidic path between a first planar surface and a second planar surface. A fluidic interface is located at one end of the planar frame. The fluidic interface has a fluidic inlet and fluidic outlet. The fluidic path further includes a well chamber having an well-substrate with a plurality of wells. The well chamber is arranged in the planar frame between the first or second surface and the well-substrate.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: August 29, 2023
    Assignee: Cepheid
    Inventors: Yuh-Min Chiang, Doug Dority, Dustin Dickens, Jennifer Glass, Reuel Van Atta
  • Patent number: 11732258
    Abstract: A functional engineered guide RNA sequence is provided including a spacer sequence and a scaffold sequence, wherein the scaffold sequence includes a primer binding site for reverse transcription.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: August 22, 2023
    Assignee: President and Fellows of Harvard College
    Inventors: Reza Kalhor, Prashant G. Mali, George M. Church
  • Patent number: 11705316
    Abstract: The invention relates to a method for the determination and visualization of the spatial distribution of tissue states of a tissue sample, wherein a mass/mobility map is acquired at each of a plurality of sample sites of the tissue sample, the signal heights at each sample site are determined at characteristic signal positions in the corresponding mass/mobility map, from which a tissue state for each sample site is calculated with the aid of a mathematical/statistical classification algorithm, and the spatial distribution of the tissue states calculated for the sample sites is represented graphically.
    Type: Grant
    Filed: May 18, 2022
    Date of Patent: July 18, 2023
    Inventors: Dennis Trede, Jan Hendrik Kobarg, Stefan Schiffler, Klaus Steinhorst
  • Patent number: 11660355
    Abstract: Several embodiments relate to engineered extracellular vesicles (EVs) using the membrane cloaking platform technology described herein, the cloaking imparting to the EVs enhanced delivery to tissues of interest, such as damaged or dysfunctional tissue. Several embodiments relate to engineering exosomes derived from cardiosphere-derived cells (CDCs) using the membrane cloaking platform technology described herein to confer enhanced tissue homing specificities, thereby leading to repair and regeneration at sites of injury. Uses of engineered EV compositions to treat diseases are also provided for in several embodiments.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: May 30, 2023
    Assignee: Cedars-Sinai Medical Center
    Inventors: Eduardo Marban, Travis Antes
  • Patent number: 11648251
    Abstract: The present invention relates to a method of determining if a patient is likely to respond to a treatment with a targeted therapy compound selected from protein kinase inhibitors, small molecule inhibitors, and monoclonal antibody-based compounds. The present invention further relates to a method of identifying a targeted therapy compound selected from protein kinase inhibitors, small molecule inhibitors, and monoclonal antibody-based compounds for personalized medicine. The present invention also relates to a method of treatment of cancer in a patient. The present invention also relates to a targeted therapy compound selected from protein kinase inhibitors, small molecule inhibitors, and monoclonal antibody-based compounds for use in a method of treatment of cancer in a patient.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: May 16, 2023
    Assignee: KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE
    Inventor: Khalid S. Abu Khabar
  • Patent number: 11643663
    Abstract: The invention relates to the ADH3 promoter; polynucleotide sequences, vectors and expression cassettes including DNA regions responsible for the regulation of the ADH3 promoter; the host cells, including these vectors and expression cassettes, and, the recombinant proteins performed with the developed cells. In the scope of the invention, deletion analyzes in the ADH3 promoter were performed to identify regions that affect promoter strength and significant data was obtained in the formation of mutant ADH3 promoters. Deletion of the nucleotides between 539 and 638 (?361 to ?262) in SEQ ID NO: 1 resulted in a 63% increase in ADH3 promoter activity. Five different synthetic promoters were created using positive regulatory regions identified and approximately 165% to 200% promoter activities were achieved with these promoters.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: May 9, 2023
    Assignee: AKDENIZ UNIVERSITESI
    Inventors: Mehmet Inan, Mert Karaoglan, Fidan Erden Karaoglan
  • Patent number: 11635363
    Abstract: Provided herein are methods and compositions for batch production of producer cells using fluorescence activated cell sorting (FACS). In some aspects, the disclosure provides a drug-selection-free method for batch production of producer cells using FACS. Such batch production methods and compositions can be further utilized to generate clonal populations of producer cells, e.g., for large-scale manufacturing of a polypeptide of interest.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: April 25, 2023
    Assignee: GENZYME CORPORATION
    Inventors: Victor R. Cairns, Jose Ignacio Sancho Chavida, Christine DeMaria
  • Patent number: 11624130
    Abstract: Some aspects of this disclosure relate to systems, apparatuses, compositions (e.g., isolated nucleic acids and vectors), and methods for improving the stability and/or solubility of proteins evolved using phage-assisted continuous evolution (PACE). In some embodiments, vectors described herein comprise nucleic acids encoding selection systems (e.g., positive and/or negative selection systems) that link expression of genes required for production of infectious phage particles to a desirable physiochemical (e.g., stability or solubility) and/or desired function of an evolved protein.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: April 11, 2023
    Assignee: President and Fellows of Harvard College
    Inventors: David R. Liu, Ahmed Hussein Badran, Tina Wang
  • Patent number: 11499972
    Abstract: A method of characterizing a glioblastoma multiforme (GBM) stem cell (GSC), comprising culturing the GSC to provide a culture, contacting a first set of aliquots of the culture with individual compounds selected from a panel of compounds, identifying two or more of the selected compounds that cause more than a threshold level of cell death in the first set of aliquots, and characterizing the GSC as suitable for treatment with one or more combinations comprising the two or more identified compounds. A panel of chemical compounds, the compounds selected by a method comprising surgically resecting the tumor, culturing a GSC derived from GBM tissue derived from a GBM tumor, contacting aliquots thereof with individual compounds selected from a panel of compounds, and identifying two or more of the selected compounds that cause more than a threshold level of cell death in the aliquots, thereby identifying the compounds.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: November 15, 2022
    Assignee: Swedish Health Services
    Inventors: Parvinder Hothi, Charles Cobbs
  • Patent number: 11492673
    Abstract: Kits and methods are provided for performing multiplex LAMP reactions. These kits and methods are directed to specific and sensitive methods of target nucleic acid detection and more specifically pathogen diagnostics such as detection of Coronavirus. The kits and methods utilize a plurality of sets of oligonucleotide primers for targeting the viral nucleic acid target.
    Type: Grant
    Filed: February 18, 2021
    Date of Patent: November 8, 2022
    Assignee: New England Biolabs, Inc.
    Inventors: Nathan Tanner, Yinhua Zhang, Gregory Patton, Guoping Ren, Zhiru Li, Nicole Nichols
  • Patent number: 11357758
    Abstract: Provided are epithelial cell spheroids including spheroids that have apical membranes and cilia that face towards the interior core of the spheroid and spheroids that have apical membranes and cilia that face away from the interior core of the spheroid. Also provided methods of making and using such spheroids.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: June 14, 2022
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Martina Gentzsch, Scott Randell, Nancy L. Quinney, Susan Boyles, Jennifer Guimbellot
  • Patent number: 11299780
    Abstract: Provided are methods of producing nucleic acid libraries. In certain aspects, the methods include combining target nucleic acids (e.g., 5? phosphorylated nucleic acids) and an oligonucleotide pool. Oligonucleotides of the oligonucleotide pool may include complementarity regions of varying length and nucleotide sequence, and a complementarity region identification sequence. In such aspects, the combining is under conditions in which oligonucleotides of the oligonucleotide pool hybridize to nucleic acids of the target nucleic acids (e.g., 5? phosphorylated nucleic acids) having overhang regions that are complementary in sequence and have corresponding lengths with respect to the complementarity regions of the oligonucleotides. Compositions and kits that find use, e.g., in practicing the methods of the present disclosure are also provided.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: April 12, 2022
    Assignee: The Regents of the University of California
    Inventor: Richard E. Green
  • Patent number: 11278610
    Abstract: The invention relates to microbial host cells engineered to produce glycoconjugate vaccines by stable integration of an acceptor protein and an oligosaccharyltransferase into the host's genome, wherein expression of the oligosaccharyltransferase is regulated.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: March 22, 2022
    Assignee: London School of Hygiene and Tropical Medicine
    Inventors: Brendan Wren, Jon Cuccui, Sherif Abouelhadid
  • Patent number: 11175282
    Abstract: The present invention provides a method to quantitatively measure the response of a patient to an immune-modulator drug that will aid clinicians in the determination of the optimal combination/posology of immunosuppressant/immune-modulator drugs. In addition, this method will open the possibility for clinicians to make the necessary adjustments in immunosuppressive therapy, as a way to avoid organ rejection to actually take place. Furthermore, this method will significantly reduce side effects of immunosuppressant drugs, optimizing therapeutic scheme and dosages, enabling the determination of the most effective immunosuppression regimen at the lower dosages for each patient individually and monitoring of treatment efficiency along time, thus opening the door to treatment personalization.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: November 16, 2021
    Assignee: BIOHOPE SCIENTFIC SOLUTIONS FOR HUMAN HEALTH S.L.
    Inventors: Javier Dotor De Las Herrerías, Marianna Di Scala, Verónica Sánchez, Isabel Portero Sánchez
  • Patent number: 11136621
    Abstract: A kit includes a microfabricated device having a top surface defining an array of microwells for receiving a sample comprising at least one cell, and a membrane for applying on the top surface of the microfabricated device to retain the at least one cell in at least one microwell of the array of microwells after the sample is loaded on the microfabricated device.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: October 5, 2021
    Assignee: GENERAL AUTOMATION LAB TECHNOLOGIES INC.
    Inventors: Paul C. Blainey, Michael W. Seely, Roman Stocker, Karsten Zengler, Scott Conradson, Peter Christey, Alexander Hallock
  • Patent number: 11105802
    Abstract: The present disclosure relates to biofragment compositions that comprise bioparticle fragments and at least one heterologous antigen-binding molecule. In some embodiments, the biofragment is typically derived from a larger, intact bioparticle that express the at least one heterologous antigen-binding molecule at the surface, and the biofragment has increased solubility to facilitate assays for antigen detection. The disclosure also relates the related methods of using and making the biofragment compositions, as well as systems and devices implementing the biofragment compositions. In some embodiments, the related methods, systems and devices do not require additional detection reagents, such as animal derived detection antibodies.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: August 31, 2021
    Assignees: SEATTLE CHILDREN'S HOSPITAL, The University of Queensland
    Inventors: Yadveer Grewal, Gerard A. Cangelosi, Muhammad J. A. Shiddiky, Matt Trau
  • Patent number: 11071983
    Abstract: Apparatus and methods for determining whether a test compound induces cell activity, changes cell activity, prevents cell activity, or inhibits cell activity. An embodiment comprises placing a test compound solution in contact with a cell suspension media containing cells, diffusing the test compound solution into the cell suspension from one or more sides, and detecting activity in the cells with respect to their distance from the side from which the test compound is diffusing. Embodiments may provide an apparatus that allows a side source, a point source, or both, from which a test compound solution diffuses into a cell suspension media and contacts cells. Detecting cell activity may involve detecting activity in a first cell group proximate to the side from which the test compound is diffusing, and detecting activity in a second cell group farther than the first cell group from the side from which the test compound is diffusing.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: July 27, 2021
    Assignee: Neuro Probe Incorporated
    Inventor: Richard H. Goodwin, Jr.
  • Patent number: 11053289
    Abstract: Yeast having modified chromosomes are provided. The chromosomes are modified such that at least one of yeast histones H3, H4, H2A or H2B are fully or partially replaced by their human histone counterparts H3, H4, H2A or H2B, respectively. Histone amino acid substitutions are included. Cell fusions with the yeast having the modified chromosomes and non-yeast cells are provided. Methods for screening test agents using the yeast are also provided. Yeast with a mutated yeast DAD1 gene, the mutated DAD1 gene encoding an E50D mutation in yeast DAD1 protein, are provided, and provide a useful genetic background for making the yeast with partially or fully replaced histone(s).
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: July 6, 2021
    Assignee: New York University
    Inventors: David M. Truong, Jef D. Boeke
  • Patent number: 11046905
    Abstract: The present invention relates to production of renewable fuels and fuel components from plant oil originating from at least one Brassica species, where said Brassica species, doped with at least one nitrogen-fixing bacteria, is cultivated to obtain Brassica seed oil, and feedstock comprising the Brassica seed oil is converted in a converting step, whereby renewable fuel or renewable fuel components are obtained. The invention also relates to a method for reducing nitrate release in renewable fuel production. Further, the invention relates to a method for reducing greenhouse gases in renewable fuel production.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: June 29, 2021
    Assignee: UPM-KYMMENE CORPORATION
    Inventors: Pekka Jokela, Liisa Ranta, Timo Lehesvirta
  • Patent number: 11029279
    Abstract: A method of detecting cells is provided. The method includes the following steps. A sensor device including a base and at least one response electrode is provided, wherein the response electrode is spaced apart from the base with respect to a gate end of the base. A test solution containing a target cell is placed on the response electrode, a first pulse voltage is applied to the response electrode, and a first detection current generated from the base is measured. A membrane potential of the target cell is changed, a second pulse voltage is applied to the response electrode, and a second detection current generated from the base is measured, wherein a sign of the first detection current and a sign of the second detection current are opposite.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: June 8, 2021
    Assignee: National Tsing Hua University
    Inventors: Yu-Lin Wang, Anil Kumar Pulikkathodi
  • Patent number: 11020463
    Abstract: The present invention provides assays and compositions to identify the risk of toxicity in a patient population with genotypic variations in specific proteins and/or protein complexes within the patient population.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: June 1, 2021
    Assignees: The J. David Gladstone Institutes, The Regents of the University of California
    Inventors: Bruce R. Conklin, Luke Judge
  • Patent number: 10941434
    Abstract: The majority of clinically used antibiotics and anticancer agents are derived from bacterial small molecules. These molecules are produced by dedicated biosynthetic gene clusters, sets of genes that are responsible for the step-wise generation of the target small molecule. Recent investigations have indicated, to the surprise of many experts, that the majority of these biosynthetic genes are inactive or ‘silent’ for unknown reasons. Thus under typical bacterial culturing conditions, these genes are not expressed and consequently the bioactive small molecule products are not synthesized. Disclosed is a method for high throughput screening of elicitors of cryptic metabolites, a method for producing cryptic metabolites, and a new family of cryptic metabolites, the acybolins, as well as their complete structural elucidation.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: March 9, 2021
    Assignee: THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventor: Mohammad R. Seyedsayamdost
  • Patent number: 10913940
    Abstract: Compositions and methods related to anucelate cells (e.g., bacterial minicells) for pesticide degradation applications including related cells, polypeptides, and vectors.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: February 9, 2021
    Assignee: UNIVERSITY OF VIRGINIA
    Inventors: Payam Pourtaheri, Sepehr Zomorodi, Zachery George Davis, Ameer Hamza Shakeel, Joseph Frank, Shaun Rafie Moshasha, Andrei Khokhlachev, Mark Kester
  • Patent number: 10870884
    Abstract: A honeycomb tube with a planar frame defining a fluidic path between a first planar surface and a second planar surface. A fluidic interface is located at one end of the planar frame. The fluidic interface has a fluidic inlet and fluidic outlet. The fluidic path further includes a well chamber having an well-substrate with a plurality of wells. The well chamber is arranged in the planar frame between the first or second surface and the well-substrate. The well chamber is in fluidic communication between the pre-amplification chamber and the fluidic outlet.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: December 22, 2020
    Assignee: Cepheid
    Inventors: Yuh-Min Chiang, Doug Dority, Dustin Dickens, Jennifer Glass, Reuel Van Atta
  • Patent number: 10784093
    Abstract: A system and method for processing long scan data from a mass spectrometer is described. The long scan data is broken into multiple discrete subsets and each of the multiple subsets are padded by adding additional strings of data on either end of the subset. Each of the multiple subsets is deconvolved and overhang errors are corrected for on each deconvolved subset. A deconvolved full data set is then assembled from the deconvolved subsets.
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: September 22, 2020
    Assignee: THERMO FINNIGAN LLC
    Inventor: Ping F. Yip
  • Patent number: 10745739
    Abstract: Disclosed are methods for cell transfection and regulating cellular behavior. More particularly, the present disclosure relates to methods of non-viral cell transfection and regulating cellular behavior using mineral coatings that allow for the enhanced transfection of cells. The mineral coatings bind polynucleotides and provide a source of calcium and phosphate ions to enhance transfection. The present disclosure also provides a high throughput platform for screening non-viral transfection of cells. The methods of the present disclosure also provide an advantageous polynucleotide delivery platform because the mineral coatings may be deposited on various medical device materials after being specifically developed using the high throughput screening platform.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: August 18, 2020
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: William L. Murphy, Siyoung Choi, Xiaohua Yu
  • Patent number: 10704099
    Abstract: The present invention relates to a method for determining a decrease in the functions of the hippocampus by using the correlation between a micro RNA (miRNA) and an N-methyl-D-aspartate receptor (NMDAR), a method for inhibiting the decrease in the functions, and a method for screening for inhibitors of the decrease in the functions.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: July 7, 2020
    Assignees: DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY, INSTITUTE FOR BASIC SCIENCE
    Inventors: Keetae Kim, Hong Gil Nam, Chand Parvez Danka Mohammed
  • Patent number: 10669562
    Abstract: The present invention relates to purified and isolated DNA sequences having protein production increasing activity and more specifically to the use of matrix attachment regions (MARs) for increasing protein production activity in a eukaryotic cell. Also disclosed is a method for the identification of said active regions, in particular MAR nucleotide sequences, and the use of these characterized active MAR sequences in a new multiple transfection method.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: June 2, 2020
    Assignee: SELEXIS S.A.
    Inventors: Nicolas Mermod, Pierre Alain Girod, Philipp Bucher, Duc-Quang Nguyen, David Calabrese, Damien Saugy, Stefania Puttini
  • Patent number: 10655102
    Abstract: The present invention provides methods for the identification, isolation and/or enrichment of human corneal endothelial cells (HCECs). In some embodiments, the method comprises a positive selection process in which a cell population containing human corneal cells is contacted with a positive affinity reagent that selectively binds to HCECs relative to cells other than HCECs (e.g., corneal keratocytes, etc.) in the population and/or a negative selection process in which a cell population containing HCECs is contacted with a negative affinity reagent that selectively binds to cells other than HCECs in the population relative to HCECs. The present invention also provides reagents and kits for the identification, isolation and/or enrichment of HCECs as well as compositions that are enriched in HCECs.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: May 19, 2020
    Assignee: Emmetrope Ophthalmics LLC
    Inventors: Jeffrey L. Goldberg, Noelia J. Kunzevitzky
  • Patent number: 10648968
    Abstract: A method for evaluating in vitro the effect of a xenobiotic (e.g., a drug) on drug metabolism in hepatocytes. The kit comprises a first culture of hepatocytes, a portion of in vitro xenobiotic-stimulated biological sample, and instructions for incubating the first culture of hepatocytes with the portion of in vitro xenobiotic-stimulated biological sample, and analyzing the activity, expression, or a combination thereof of a biomarker in the hepatocytes to evaluate the effect of the xenobiotic on drug metabolism in the hepatocytes.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: May 12, 2020
    Assignee: XenoTech, L.L.C.
    Inventors: Maciej Czerwinski, David Benjamin Buckley, Faraz Kazmi
  • Patent number: 10640537
    Abstract: The present invention provides for a system comprising (a) a first nucleic acid comprising a nucleotide sequence encoding a nucleotide sequence of interest operatively linked to a promoter comprising a repressor polypeptide binding site, and (b) a second nucleic acid comprising a nucleotide sequence encoding a repressor polypeptide having at least 70% amino acid identity with EilR, SmvR, KmrR, RcdA, or QacR; wherein expression of the nucleotide sequence of interest from the promoter is induced by the presence of a hydrophobic inducer, such as a hydrophobic cation inducer, such as a triarylmethane, acridine, phenazine, phenothiazine, or xanthene.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: May 5, 2020
    Assignee: The Regents of the University of California
    Inventor: Thomas L. Ruegg
  • Patent number: 10632169
    Abstract: Biomarkers are not as commonly used in ALS drug development as in the drug development process for oncology. Biomarkers are important component of the ALS drug development pathway to demonstrate drug effect and target engagement. In a recent Phase 2A double-blind, randomized, placebo controlled clinical trial with GM604 (AKA MNTF, GM6), where ALS patients were treated with six doses of GM604 for two weeks and then continued to be evaluated for disease progression until 10 weeks after cessation of GM604 treatment, it was demonstrated that GM604 can modulate expression of ALS disease related genes, through pathways that bring about homeostasis of pertinent ALS biomarkers. The statistical significance in biomarker changes also correlate with treatment effects in clinical observations.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: April 28, 2020
    Assignee: Genervon Biopharmaceuticals, LLC
    Inventors: Pui-Yuk Dorothy Ko, William R. Swindell
  • Patent number: 10626445
    Abstract: The present invention generally relates to a set of early developmental reference data or “lineage scorecard” for stem cells, and methods, systems and kits to generate a lineage scorecard for predicting the functionality and suitability of stem cell lines. In some aspects, methods for generating a scorecard comprises measuring the gene expression of a plurality of early developmental genes, such as pluripotent, early ectoderm, early mesoderm and early endoderm genes to predict the pluripotency and differentiation potential of the stem cell line and its functionality and/or suitability for a desired use. In some embodiments, a reference scorecard can be compared with the test stem cell line scorecard to accurately predict the utility and/or identify specific characteristics of the stem cell line, e.g., to determine its suitability for downstream applications, e.g., therapeutic use, drug screening, toxicity assays, differentiation into a desired cell lineage, etc.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: April 21, 2020
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Alexander Meissner, Alexander Tsankov, Veronika Akopian
  • Patent number: 10591486
    Abstract: A method for detecting an interaction between one or more protein bait and one or more candidate prey in a eukaryotic cell, comprising the steps of: a) providing an eukaryotic cell expressing (i) one or more protein bait, and (ii) one or more candidate prey, wherein said protein bait comprises a bait moiety and a polymerized-tubulin binding moiety. b) determining the occurence of an interaction between said one or more protein bait and said one or more candidate prey in the eukaryotic cell, wherein said protein bait is bound to polymerized tubulin in the eukaryotic cell, thereby localizing said one or more candidate prey along said polymerized tubulin, thereby detecting said interaction.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: March 17, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE D'EVRY — VAL D-ESSONNE
    Inventors: David Pastre, Michel Cailleret, Patrick Curmi, Mirela Boca
  • Patent number: 10591458
    Abstract: Embodiments described herein are directed to devices for supporting growth of anisotropic muscle tissue layers and in vitro readout and quantification of force generated by the tissue layers using one or more strain-sensing elements integrated into the device. Embodiments also include multiplexed apparatuses of multiple independent devices, methods of fabricating the devices and apparatuses, and methods of using the devices and apparatuses.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: March 17, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: Kevin Kit Parker, Johan Ulrik Lind, Jennifer Ann Lewis, Joost Johan Vlassak, Hongyan Yuan, Travis Alexander Busbee, Ian Perkins, Christophe Chantre
  • Patent number: 10584369
    Abstract: The invention provides a method for determining the activity of an inhibitor of a target protein that has a deleterious effect on cell growth. The principle of the claimed method is that a compound that inhibits the function of an overexpressed protein will relieve the detrimental effect of such overexpression in a concentration-dependent manner, thereby allowing the determination of the activity of the compound in inhibiting its target protein in live cells.
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: March 10, 2020
    Assignee: Senex Biotechnology, Inc.
    Inventors: Igor B Roninson, Donald C Porter, Serena Altilia